Background: The impact of antimicrobial resistance (AMR) has placed it among one of the top public health problems worldwide. AMR has increased the global infectious disease burden and put a greater strain on health systems. This review sought to contribute more evidence on this issue of AMR in the Central African Region, by determining the overall bacterial pathogens resistance rate and pathogen specific resistance rate with respect to antimicrobial agents common in the region.
Introduction
The impact of antimicrobial resistance (AMR) has placed it among one of the top public health problems worldwide [1] The emergence of AMR and its rapid acceleration among priority pathogens has hindered the effectiveness of antibiotic therapy in many clinical conditions [2] . This has resulted in increased mortality, morbidity as well as higher socio-economic costs. Projections have shown that at this rate, by 2050, an estimated 10 million deaths will occur annually with an associated cumulative economic cost of about US$100 trillion worldwide [2, 3] . AMR has therefore increased the global infectious disease burden and put a greater strain on health systems. It is critical that every country, regardless of income level, should proactively take steps against AMR. Containment will only occur with concerted, coordinated global action [2] . Inaction breeds the risk of reversing the progress made against public health threats of today, such as HIV and malaria, and a likely resurgence of diseases of the past, including infections that were hitherto once treatable like Pneumonia [4] . The World Health Organization (WHO) has recognized the public health threat of AMR and has continuously urged countries to combat it [2] . A WHO global action plan for AMR was adopted in 2015 with recommendations for countries to develop a national AMR action plan, re-inforce surveillance systems, and provide a knowledge and evidence base for action and advocacy, in order to enhance the collection, and analyses of standardized, comparable, and validated data on AMR that can be shared among countries [5] . However, a recent status report on the African region showed that only 2 countries (4.3%) had a national AMR plans in place while only 7 countries (14.9%) have overarching national infection prevention and control (IPC) policies [6] . Additionally, in Africa, significant gaps in surveillance, standard methodologies and data sharing have been reported elsewhere [7] .
In line with this Global Action Plan, and to meet needs specific to Africa, the Africa Centers for Disease Control is establishing Anti-Microbial Resistance Surveillance Network (AMRSNET) which is a network of public health institutions and leaders from human and animal health sectors who will collaborate to measure, prevent, and mitigate harms from AMR organisms [3] . This will be achieved by improving surveillance of AMR organisms among humans and animals, delaying emergence of AMR, limiting transmission of AMR and mitigating harm among patients infected with AMR organisms [3] . Despite this global recognition, in some parts of the world like in Central Africa, the sheer magnitude of AMR threat is not fully understood. Available data shows that the Central African Region shares the worldwide trend of increasing drug resistance [8, 9] with resistance being reported for every major class of antibiotic in both community and health-care settings. The emergence, persistence and transmission of AMR patterns in developing countries have been growing as a result of a myriad of factors; genetic capabilities of pathogens, high burden of microbial infections, lack of monitoring of antimicrobial resistance [3, 10, 11] .
Even though some studies have reported a high prevalence of AMR in sub-Saharan African countries [7] , overall, there is still a scarcity of evidence on the real impact of AMR in the region which is further compounded by a considerable variation in this existing data. A WHO global report on antimicrobial resistance, showed that the African region has one of the largest gaps in available evidence on the prevalence of AMR [5] . Also, an external quality assessment reported considerable deficits in antimicrobial susceptibility testing in many African countries [12] . Some studies in Central Africa have reported on the trends of antimicrobial resistance in specific clinical syndromes, while others have focused on specific bacteria isolates [13] . However, there is still limited and up to date information on AMR representation in the Central African Region. The last review of published literature on bacterial resistance in Central Africa was carried out 10 years ago and revealed alarming resistance rates in nearly all pathogens in the region [13] . A situational analysis of antimicrobial drug resistance in Africa stated that the expansion of resources and the technological advances observed in the past decades has led to the availability of larger amounts of drugs in developing countries than ever before, with antibiotics being the most frequently prescribed drugs in hospitals [14] . The dearth of evidence of AMR in the region can be attributed to a number of factors ranging from the lack of established national or regional AMR surveillance systems, inadequate laboratory capacity, lack of resources, weak infrastructures and limited standard operating procedures [3] . It is in this light that, our review sought to update the evidence on this topic, by determining the overall resistance rate of bacterial pathogens and reported resistance of each pathogen with respect to antimicrobial agents common in the Central African region. Establishing the resistance rates will enhance and provide stakeholders with a current status, identified gaps and modifiable causes of AMR in the region.
Methodology
The review team comprised of experts in microbiology, anti-microbial resistance, epidemiology, medicine, and systematic reviews methodology. The research design that was applied to this study was a review of the available studies on anti-microbial resistance in Central African Countries. The review permitted was designed to conduct a comprehensive search for primary studies on the focused research questions, selecting studies using clear and reproducible eligibility criteria, critically appraising study quality and completing a synthesis of findings according to pre-determined and explicit methods [15] . Data from all studies on AMR in Central African states were combined and observed for trends and extend of uniformity in the available results. We it was anticipated that by studying similar outcomes across a wide variety of contexts, settings and study designs, we would be able to assess the rigor of available evidence on AMR in the region. Additionally, considering that reviews are considered among the best source of evidence [16] , the study was also intended to provide pooled estimates about the impact of AMR in the region, which may be more reliable than evidence from single studies [17] . 
Search strategy
We initially conducted a scoping search done to identify existing reviews on AMR in Central Africa, and this permitted us to further highlight relevant search terms and clarify inclusion and exclusion criteria [18] as well as avoid duplication of efforts. For this review, we searched several electronic databases for published and unpublished articles from 2008 to 2018. We decided to start our search in 2008 to coincide with the last published review on this topic in Central Africa [13] . We used the Boolean strategy to search through the following databases; Pubmed, Medline, Embase, Web of Sciences, Google scholar, Cochrane Library, African Journal Online, MEDLINE, and
Scopus. In consultation with regional AMR experts, colleagues and members of our research team, we focused on priority microbial pathogens and associated disease conditions that are common within the Central African Region.
We used a combination of Medical Subject Heading (MeSH) and free text terms to search through these databases using the following key words; We sought to find relevant databases for research in the region, but none was identified for this study. In order to further extend our evidence base, and minimize publication bias due to selective availability of papers, we decided to search for grey literature (conference abstracts, research reports, book chapters, unpublished data, dissertations and policy documents). Finally, we manually combed through bibliographies and performed hand searching of key journals on the topic. The most recent comprehensive search for each database was March 25 th , 2019, and all relevant studies were exported to Zotero bibliographic software.
Eligibility criteria
According to our study design and the research topic, we established predefined criteria for study retention in the review as follows
Study content: All published (and in press) research articles focusing on Antimicrobial (Bacterial) Drug
Resistance (including MDR and TDR).
Timeframe:
Papers are eligible if published in or after the year 2008.
Context:
We sought studies carried out in any of the 10 Economic Community of Central African States 
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Brazzaville and Equatorial Guinea, Burundi, Rwanda, the Democratic Republic of Congo (DRC) and Sao Tome and Principe.
Study design/setting: Cross-sectional, longitudinal, longitudinal, Prospective and surveillance studies were
sourced either conducted within a Laboratory, hospital or community environment.
Population:
Individuals of all age groups and sex.
Setting:
Community, laboratory and healthcare facilities.
Language: English and French

Studies with the following characteristics were excluded
i. Antimicrobial resistance studies that focused on animal subjects
ii.
Antimicrobial resistance studies that focused on antifungal, antiviral and antiprotozoal
iii.
Studies that reported data for less than 10 patients iv.
Studies that reported data for less than 10 isolates of a particular pathogen
Data screening and extraction
We first of all removed all duplicate articles that we found from the various databases. We then performed an initial screening of the titles and abstracts on the basis of the eligibility criteria stated above in order to validate their selection as part of this review. Next, we performed full text screening of selected studies. All the articles that met our inclusion criteria were retained for data extraction. This was done using an electronic standardized data extraction template that was designed by the team in line with the study objectives, the inclusion criteria, and made up of relevant study components for data analysis. This data extraction template was first pilot tested on a representative sample of articles. The titles, abstract and full text screening as well as data extraction was done independently and in triplicate (ETA, CN and FSW) with disagreements resolved via consensus, or by a tie breaker (DEAA).
Data analysis
The data was extracted data into an Excel sheet and exported to SPSS version 21 for analysis. Considering that the studies on AMR in the Central African region were heterogeneous and methodologically diverse (context, population, study design, setting, and type of AMR outcomes), a formal study quality assessment nor a metaanalysis of the selected papers could not be done. The data was collated, summarized and categorized in order to perform appropriate statistical analyses. Median statistics was performed and inter quarter range computed if more than three papers had assessed the resistance rates. We calculated median resistance (MR) and interquartile range number of articles available per country. Since the number of studies from hospital/in-patient settings was small, they were combined and median percentages with interquartile ranges were generated.
Results and Discussions
Data and study characteristics
After a careful examination, taking into consideration the inclusion and exclusion criteria, Out of 130 studies that were scoped, 30 studies were found eligible for the review. The adapted PRISMA flow diagram as shown in Figure   1 presents the inclusion and exclusion process. It worthy to note that, out of the 30 studies that were included for this review, seven of the studies were carried out in Cameroon [10, [19] [20] [21] [22] [23] [24] , 6 in the Democratic Republic of Congo [25] [26] [27] [28] [29] [30] , 5 in Gabon [31] [32] [33] [34] [35] , 4 in Central Africa
Republic [36] [37] [38] [39] and Rwanda [40] [41] [42] [43] and one study each in Chad [44] , Congo Brazaville [45] , Equatorial Guinea [46] , Sao Tome and Principe [47] respectively. We found no study for Burundi. 
Overall bacterial patterns resistance to commonly used antimicrobial drugs
The most commonly reported bacterium was Salmonella spp and been reported by 16 studies with a median resistance rate of 45. 
Multidrug resistant tuberculosis (MDR TB)
Although overall global incidence is falling, tuberculosis (TB) still claims the lives of approximately 1.6 million people each year [44] . [49] showed that, the overall resistance rate in new cases was 16.9% compared to 41.6% in previously treated cases.
Isoniazid resistance was the most frequent (12.5% and 16.6% respectively) in the two groups (new cases and previously treated cases), while multidrug resistance was observed in 1.7% and 25% of new and previously treated cases, respectively. It has been shown that level of MDR-TB among TB patients in Rwanda is high compared to
other Central African states. This was establish that Umubyeyi et al. [50] , of 616 strains from new cases, 6.2% were resistant to isoniazid, 3.9% to rifampicin and 3.9% were multidrug-resistant TB. Among 85 strains from previously treated cases, the prevalence of resistance was 10.6%, 10.6% and 9.4% (MDR-TB strains) respectively. Eight MDR cases showed additional resistance to ethambutol and streptomycin. In Cameroon, a study by Noeske et al. [48] reported 26 patients (12%) out of 438 retreatment cases harbored multi-drug resistant (MDR) strains in the Littoral region of the country.
Extensively drug-resistant tuberculosis (XDR TB)
Worryingly, cases of extensively drug-resistant TB (XDR-TB) have also occurred, although more infrequently.
Owing to the fact that XDRTB is resistant to many first-line and reserve TB medicines, the current treatment options are extremely limited. In some cases, these strains of TB are virtually untreatable. However, we didn't find any published study conducted on extensively drug-resistant TB (XDR-TB) among the 10 Economic Communities of Central African States (ECCAS).
Vibrio cholerae resistance
Only 1 study [51] reported Vibrio cholerae resistance. In the study, Vibrio cholerae was resistant to Nalidixic acid 
Staphylococcus aureus resistance
In Central African states, resistance data for S. aureus were reported in 8 studies [32, 45, [52] [53] [54] [55] [56] 59] 
Methicillin-resistant Staphylococcus aureus (MRSA)
Methicillin-resistant Staphylococcus aureus (MRSA) is a global health concern, but there are few data from Central Cefixime 100 (à) à = IQR could not be calculated because we had less than three papers that assessed resistance rates. 
Shigella spp resistance
Five studies [23, 34, 36, 37, 57] were found in our search. Two-thirds reported on outbreak investigations, and Shigella dysenteriae type 1 was the predominant serotype. The five studies that were found in the search studied the resistance of Shigella Spp to 12 antibiotics and revealed that Shigella showed resistance of over 70% of 6 drugs (amoxicillin, Tetracycline, Trimethroprim sulfamethoxazole, doxycycline and Strptomycin). On the other hand shigella was least resistance to Cefotaxime and gentamycin (10.6% and 0.34% resistance respectively). A study by Njunda et al. [23] in Cameroon, reported that of 223 stool samples cultured, 10 (4.5%) yielded Shigella species.
They went ahead to show that Isolation rate was observed to be more in children below 15 years (7.89%), and also higher in rural areas (6.35%). This study also revealed that all 10 isolates showed resistance to at least two antibiotics and 9 (90%) were multi-drug resistant. The highest resistance rates were encountered with tetracycline (98.5%) and streptomycin (97%). Least resistance was observed with gentamycin (034%). Table 7 shows the median resistance rates of Shigella spp to 12 antibiotics. à = IQR could not be calculated because we had less than three papers that assessed resistance rates. 
Pathogen
Salmonella spp. resistance
It is worthy no note that, Salmonella enterica serotype Typhi and the nontyphoid S. enterica (NTS) are leading causes of bacteremia in Africa, though little information is available from Central Africa. Ampicillinbetalactamaseinhibitor 3.9 (à) à = IQR could not be calculated because we had less than three papers that assessed resistance rates. 
Non-typhoid Salmonella (NTS) resistance
Two studies [27, 28] specifically addressed Non-typhoid Salmonella (NTS) resistance in the Central African region.
The general study characteristics were similar to those reporting on S. Typhi. As part of a microbiological surveillance study in DR Congo, blood cultures were collected between 2007 and 2011. Isolated NTS were assessed for serotype and antimicrobial resistance, including decreased ciprofloxacin susceptibility and extended-spectrum beta-lactamase (ESBL) production. In total, 233 NTS isolates (representing 23.6% of clinically significant organisms) were collected, mainly consisting of Salmonella Typhimurium (79%) and Salmonella Enteritidis (18%).
The majority of NTS were isolated during rainy season, and from children ≤ 2 years old. MDR, decreased ciprofloxacin susceptibility, azithromycin and cefotaxime resistance were 80.7%, 4.3%, 3.0% and 2.1% respectively. Resistant rates were higher four antibiotics that is above 80%. Table 9 shows the median resistance rates of Non-typhoid Salmonella to 7 antibiotics. Multidrug resistance 80.7 (à) à = IQR could not be calculated because we had less than three papers that assessed resistance rates. 
Pathogen
Pseudomonas aeruginosa resistance
Five studies [24, 35, 39, 41, 63] [21] in Cameroon, noted combined resistance to at least two antibiotics in all strains. Ampicillinbetalactamaseinhibitor 92.6 (à) à = IQR could not be calculated because we had less than three papers that assessed resistance rates. verocytotoxigenic E. coli (VTEC). We retrieved data on E. coli predominantly from urine and faeces, and rarely from blood or pus. The reported and mean resistance rates were high for all commonly used antibiotics but also for amoxicillin/clavulanic acid and first-generation cephalosporins. There is growing resistance of several bacteria to a class of antibiotics known as cephalosporins and carbapenems, which, for many conditions, represent the "last line" of effective treatment [68] . 
Conclusion
Antimicrobial agents, of which antibiotics are a subset, have saved hundreds of millions of lives from infectious diseases. Antimicrobial resistant (AMR) organisms are increasing globally, threatening to render existing treatments ineffective against many infectious diseases. Drug resistant strains of bacteria, prolong illness, increase case-fatality, facilitate transmission, and increase treatment costs. In summary, our review highlights two important findings: first, there is huge gap of data regarding antimicrobial resistance in the Central African Region. Few studies were found in more than a third of the countries on the region not having recent data on the issue of AMR. Second, a high level of drug resistance exists to commonly prescribed antibiotics in the Central African region. We recommend the standardization and quality of the microbiological identification and susceptibility/resistance testing methods as well as Surveillance to be improved inorder to allow national and international organizations to monitor the extent of the AMR problem. All of the identified areas of concern need urgent attention by the global health community in order to halt the public health threat associated with spreading AMR. In line with Africa CDC [3] , initiatives such as the
